Bausch + Lomb (BLCO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$5.3B

Revenue (quarter)

$1.4B

Revenue growth (year over year)

+9.08%

Gross profit (trailing twelve months)

$3.3B

Gross margin

61.44%

Net income (trailing twelve months)

−$163.0M

Net income (quarter)

−$10.0M

Net income growth (year over year)

+82.76%

Net margin

−3.06%

Return on equity

−2.67%

EPS (trailing twelve months)

−$0.48

Book value per share

$17.86

P/E (trailing twelve months)

—

Price to book

0.89

Debt to assets

53.50%

Payout ratio

—

Dividend yield

—

Company profile

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

• Is Bausch + Lomb (BLCO) profitable?

  No. Bausch + Lomb reported a net loss of $163.0M over the trailing twelve months.

• How much revenue does Bausch + Lomb (BLCO) make?

  Bausch + Lomb generated $5.3B in revenue over the trailing twelve months, up 9.08% year over year.

• How do I buy stock in Bausch + Lomb (BLCO)?

  BLCO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.